Onkologie. 2022:16(1):20-24 | DOI: 10.36290/xon.2022.004

New treatment options for metastatic renal cell carcinoma

Alexandr Poprach, Radek Lakomý

Klinika komplexní onkologické péče, Masarykův onkologický ústav a LF MU, Brno

The dynamic development in the treatment options for metastatic renal cell carcinoma is remarkable. Until a few years ago, we thought that the era of targeted treatment was ending and that this therapy would be replaced by immunotherapy with checkpoint inhibitors. Subsequently, however, it turned out that the administration of checkpoint inhibitors alone, or a their combination, would probably not be sufficient, and in some patients a combination of targeted therapy and immunotherapy would be more appropriate. It is currently considered to be the most topical submission of these combinations concomitantly. Although it is necessary to wait for data from both clinical studies and real practice, whether sequential administration is not therapeutically comparable at the cost of less toxicity. In this review, we will look at the latest results of studies that examine the effectiveness of modern treatment in patients with metastatic renal cell carcinoma, especially in the first-line treatment.

Keywords: renal cell carcinoma, targeted treatment, immunotherapy, overall survival.

Published: February 22, 2022  Show citation